SIGLEC7 Human
Sf9, Baculovirus cells.
Sialic Acid Binding Ig Like Lectin 7, QA79 Membrane Protein, SIGLEC-7, D-Siglec, AIRM-1, CDw328, AIRM1, P75, Sialic Acid Binding Ig-Like Lectin 19, Pseudogene, Adhesion Inhibitory Receptor Molecule 1, Siglec-7, Sialic Acid Binding Ig-Like Lectin, Pseudogene 2, Sialic Acid Binding Immunoglobulin-Like Lectin 7, Adhesion Inhibitory Receptor Molecule 1, Sialic Acid Binding Ig-Like Lectin 7, Sialic Acid-Binding Ig-Like Lectin 7, CD328 Antigen, SIGLEC19P, P75/AIRM1, SIGLECP2, CD328, QA79.
Greater than 90.0% as determined by SDS-PAGE.
Description
SIGLEC7 Human Recombinant produced in Sf9 Baculovirus cells is a single, glycosylated polypeptide chain containing 577 amino acids (19-353a.a.) and having a molecular mass of 64.2kDa. SIGLEC7 is expressed with a 239 amino acid hIgG-His-tag at C-Terminus and purified by proprietary chromatographic techniques.
Product Specs
Sialic Acid Binding Ig Like Lectin 7, QA79 Membrane Protein, SIGLEC-7, D-Siglec, AIRM-1, CDw328, AIRM1, P75, Sialic Acid Binding Ig-Like Lectin 19, Pseudogene, Adhesion Inhibitory Receptor Molecule 1, Siglec-7, Sialic Acid Binding Ig-Like Lectin, Pseudogene 2, Sialic Acid Binding Immunoglobulin-Like Lectin 7, Adhesion Inhibitory Receptor Molecule 1, Sialic Acid Binding Ig-Like Lectin 7, Sialic Acid-Binding Ig-Like Lectin 7, CD328 Antigen, SIGLEC19P, P75/AIRM1, SIGLECP2, CD328, QA79.
Sf9, Baculovirus cells.
ADPQKSNRKD YSLTMQSSVT VQEGMCVHVR CSFSYPVDSQ TDSDPVHGYW FRAGNDISWK APVATNNPAW AVQEETRDRF HLLGDPQTKN CTLSIRDARM SDAGRYFFRM EKGNIKWNYK YDQLSVNVTA LTHRPNILIP GTLESGCFQN LTCSVPWACE QGTPPMISWM GTSVSPLHPS TTRSSVLTLI PQPQHHGTSL TCQVTLPGAG VTTNRTIQLN VSYPPQNLTV TVFQGEGTAS TALGNSSSLS VLEGQSLRLV CAVDSNPPAR LSWTWRSLTL YPSQPSNPLV LELQVHLGDE GEFTCRAQNS LGSQHVSLNL SLQQEYTGKM RPVSGVLLLE PKSCDKTHTC PPCPAPELLG GPSVFLFPPK PKDTLMISRT PEVTCVVVDV SHEDPEVKFN WYVDGVEVHN AKTKPREEQY NSTYRVVSVL TVLHQDWLNG KEYKCKVSNK ALPAPIEKTI SKAKGQPREP QVYTLPPSRD ELTKNQVSLT CLVKGFYPSD IAVEWESNGQ PENNYKTTPP VLDSDGSFFL YSKLTVDKSR WQQGNVFSCS VMHEALHNHY TQKSLSLSPG KHHHHHH.
Product Science Overview
Sialic acid-binding immunoglobulin-like lectin 7 (Siglec-7) is a member of the Siglec family, which are sialic acid-binding proteins predominantly expressed on immune cells. Siglec-7 is known for its role in modulating immune responses and maintaining immune homeostasis. This article delves into the structure, function, and significance of Siglec-7, particularly focusing on its recombinant form used in research and therapeutic applications.
Siglec-7 is a transmembrane protein characterized by its immunoglobulin (Ig)-like domains. It consists of an extracellular region with three Ig-like domains, a transmembrane region, and a cytoplasmic tail containing immunoreceptor tyrosine-based inhibitory motifs (ITIMs). These ITIMs are crucial for transmitting inhibitory signals within the cell .
Siglec-7 is constitutively expressed on natural killer (NK) cells, monocytes, and a subset of CD8+ T cells . Its expression can be modulated in response to various stimuli, including cytokines and interactions with other cells.
The primary function of Siglec-7 is to recognize and bind sialic acids, which are commonly found on the surface of cells and pathogens. This binding is sialic acid-dependent and plays a significant role in immune regulation. Siglec-7 preferentially binds to α(2,8)-linked disialic acid and α(2,6)-linked sialic acid .
One of the key roles of Siglec-7 is to inhibit the activation of NK cells. When Siglec-7 binds to its ligands on target cells, it transmits inhibitory signals through its ITIMs, leading to the suppression of NK cell cytotoxicity. This mechanism helps prevent excessive immune responses and maintains immune tolerance .
Siglec-7 has been implicated in various diseases, particularly those involving immune dysregulation. For instance, in HIV-1 infection, Siglec-7 expression is reduced on NK cells from viremic patients. This reduction is associated with increased susceptibility to infection and disease progression . Additionally, cancer cells often upregulate Siglec ligands to evade immune surveillance by engaging Siglec-7 and other inhibitory receptors on immune cells .
Recombinant Siglec-7 is a form of the protein produced through recombinant DNA technology. It is used extensively in research to study the protein’s structure, function, and interactions. Recombinant Siglec-7 can be produced in various expression systems, including bacterial, yeast, and mammalian cells, each offering distinct advantages in terms of yield, post-translational modifications, and functionality.
Given its role in immune regulation, Siglec-7 is a potential target for therapeutic interventions. Modulating Siglec-7 activity could enhance immune responses against infections and tumors. For example, blocking Siglec-7 interactions with its ligands may boost NK cell activity and improve anti-tumor immunity . Conversely, enhancing Siglec-7 signaling could be beneficial in conditions characterized by excessive immune activation, such as autoimmune diseases.
